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BaCkground
Metoprolol is a selective beta-adrenergic antagonist 
commonly used in the management of acute myocar-
dial infarction (MI), angina, hypertension, and cardiac 
arrhythmias. Metoprolol is supplied as a racemic 
 mixture of S and R enantiomers. The S enantiomer is 
primarily responsible for beta-receptor antagonism 
and is beta-1 selective, whereas the R enantiomer has 
lower affinity and selectivity.1,2 Metoprolol is prima-
rily metabolized by the liver, with an estimated 65% of 
a dose O-demethylated, 10% alpha-hydroxylated, and 
10% N-dealkylated.3 Cytochrome P-450 2D6 (CYP2D6) 
is responsible for alpha-hydroxylation and some 
O-demethylation of metoprolol with stereospecificity 
favoring metabolism of the R enantiomer.4 Alternate 
metabolic pathways are high affinity, low capacity, 
and readily saturable and favor metabolism of the S 
enantiomer.4 Individuals exhibiting the CYP2D6 exten-
sive metabolizer (EM) phenotype have greater clear-
ance of the R enantiomer and greater relative plasma 
concentrations of the S enantiomer.5-7 Individuals 
exhibiting the CYP2D6 poor metabolizer (PM) pheno-
type show approximately equal clearances and plasma 
concentrations of the R and S enantiomers.5-7
Studies have demonstrated an influence of dosage release 
formulations on drug interactions and enantiomeric plasma 
concentrations. Metoprolol is a commonly used beta- 
adrenergic antagonist metabolized by CYP2D6. The 
CYP2D6 inhibitor paroxetine has previously been shown to 
interact with metoprolol tartrate. This open-label, rand-
omized, 4-phase crossover study assessed the potential 
differential effects of paroxetine on stereoselective pharma-
cokinetics of immediate-release (IR) tartrate and extended-
release (ER) succinate metoprolol formulations. Ten healthy 
participants received metoprolol IR (50 mg) and ER (100 mg) 
with and without paroxetine coadministration. Blood sam-
ples were collected over 24 hours for determination of meto-
prolol plasma enantiomer concentrations. Paroxetine 
coadministration significantly increased S and R metoprolol 
area under the plasma concentration-time curve from time 
0 to the 24-hour blood draw (AUC0-24h) by 4- and 5-fold, 
respectively for IR, and 3- and 4-fold, respectively, for ER. 
S/R AUC ratios significantly decreased. These results 
demonstrate a pharmacokinetic interaction between par-
oxetine and both formulations of metoprolol. The interac-
tion is greater with R metoprolol, and stereoselective 
metabolism is lost. This could theoretically result in 
greater beta-blockade and lost cardioselectivity. The mag-
nitude of the interaction was similar between metoprolol 
formulations, which may be attributable to low doses/drug 
input rates employed.
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Paroxetine is a widely used selective serotonin 
reuptake inhibitor that inhibits CYP2D6 and therefore 
interacts with a number of CYP2D6 substrates. A 
study in healthy volunteers showed that coadminis-
tration of paroxetine with immediate-release (IR) 
metoprolol resulted in a loss of stereospecific meto-
prolol metabolism and increases in metoprolol area 
under the plasma concentration-time curve (AUC), 
maximum plasma concentration (Cmax), and elimina-
tion half-life.8 A second study of post-MI patients 
showed increases in AUC when paroxetine was coad-
ministered with either IR metoprolol tartrate 
or extended-release (ER) metoprolol succinate but 
made no distinction between the 2 formulations in 
analysis.9
Dosage release formulations influence the nature 
and magnitude of some metabolic drug interactions 
and may affect enantiomeric plasma concentration 
ratios if metabolism is stereoselective.10-12 Immediate-
release preparations may theoretically be more sus-
ceptible to drug interactions because high drug 
input rates are more likely to achieve concentrations 
that saturate hepatic metabolism. The objective of 
this study was to assess the differential effects, if 
any, of paroxetine administration on the single-dose 
pharmacokinetic (PK) properties of metoprolol IR 
and ER, with the hypothesis that the IR formulation 
would have a greater magnitude of interaction.
Methods
study design
This study employed an open-label, randomized, 
crossover design. Participants were assigned to 
receive metoprolol IR and ER study phases (2 each) 
in random order. Paroxetine coadministration was 
randomly assigned to an IR phase and an ER phase. 
Metoprolol was given as a single oral dose of either 
50 mg metoprolol IR or 100 mg metoprolol ER 
(Toprol XL). These doses were chosen to be easily 
detectable in blood while representing lower doses 
common in clinical practice to minimize the poten-
tial for toxicity. Paroxetine was administered at 
steady-state dosing to reflect paroxetine dosing in 
clinical practice, up and down titrated for safety 
reasons. Immediate-release paroxetine (10 mg) was 
given orally once daily for 2 days, then twice daily 
for 5 days, then twice daily on the day of metoprolol 
dosing, then daily for 4 days afterward. On metopro-
lol dosing days, participants received paroxetine (10 
mg) concurrently with a single oral dose of metopro-
lol and a second oral paroxetine dose (10 mg) 12 
hours later. A minimum 7-day washout separated 
metoprolol doses, and a minimum 6-day washout 
separated the last previous paroxetine dose from off-
paroxetine metoprolol doses.
Participants were required to fast from 10 pm the 
night prior to each admission, with water ad lib 
except for 1 hour before and 2 hours after metoprolol 
dose. A standardized meal was given at 12 pm. 
Metoprolol administration phases were carried out 
in the General Clinical Research Center and Michigan 
Clinical Research Unit at the University of Michigan 
Hospital. Study medications were dispensed by the 
hospital pharmacy and given with 8 oz of water. All 
participants received a standardized lunch and din-
ner prepared and monitored by the research center. 
This study protocol was approved by an Institutional 
Review Board of the University of Michigan Hospital, 
and all participants provided written informed con-
sent prior to participation.
Participants
Prospective participants were eligible for inclusion 
in the study if they were nonsmoking healthy adults 
18 to 45 years of age, not regularly taking any pre-
scription or nonprescription medications (including 
natural products or supplements), willing to avoid 
all nonstudy medications during the study period, 
willing to adhere to dietary restrictions as required, 
and willing to comply with the study requirements, 
including documenting medication ingestion and 
adverse effects.
Prospective participants were excluded if they 
had any clinically significant abnormal findings on 
history or physical exam, including resting heart 
rate less than 60 beats per minute, blood pressure 
less than 110/70 mm Hg, significantly abnormal 
findings on a screening electrocardiogram, or abnor-
mal laboratory values at baseline. Other exclusion 
criteria included allergy or serious adverse reaction 
to any of the medications used in the study (includ-
ing heparin), the presence of any condition that the 
investigator felt would interfere with successful 
completion of the study, and concurrent participa-
tion in any other study. Women who were breast-
feeding, pregnant, or of childbearing potential and 
not on reliable contraception were ineligible.
sample Collection
Participants had an intravenous catheter placed in 
an antecubital or forearm vein by 8 am on metoprolol 
dosing days. Blood samples (7 mL/sample) were 
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then collected into tubes containing ethylene diami-
netetracetic acid (EDTA) immediately prior to drug 
administration (time 0) and at 0.25, 0.5, 0.75, 1, 1.5, 
2, 4, 6, 8, 10, and 12 hours after administration. 
Patency of the catheter was maintained with 3 mL of 
heparin 10 units/mL solution. Then, 3 mL was with-
drawn from the catheter dead space and discarded 
immediately prior to each blood sample. The cathe-
ter was withdrawn after the 12-hour blood sample. 
Participants were allowed to leave the study center 
and return for the final blood sample (7 mL) drawn 
by venipuncture at 24 hours. All blood samples 
were centrifuged at 4°C and approximately 2800 
rpm within 1 hour of collection. Plasma was then 
collected and stored at –70°C until analysis.
Potential pharmacodynamic effects of metoprolol 
were measured by heart rate, heart rhythm, and 
blood pressure (BP) at each blood sampling time. 
Following blood draws, heart rate and rhythm were 
measured by a 3-lead electrocardiogram. Next, a sit-
ting BP was obtained with an automated blood pres-
sure machine a minimum of 3 times per sample, with 
no difference >10 mm Hg between systolic readings.
Bioanalytical Methods
Plasma metoprolol enantiomer concentrations were 
quantified at an independent outside laboratory 
(NSF International, Ann Arbor, Michigan). In brief, 
S and R enantiomers were analyzed by a high- 
pressure liquid chromatography (HPLC) system 
(Agilent Technologies, Santa Clara, California). The 
method employed a 2.0-mm chiral cellobiohydro-
lase column and a mobile phase consisting of 5% 
2-propanol in 10 M sodium phosphate buffer (pH 
6.0) with 50 µM disodium EDTA at a flow rate of 
0.25 mL/min. Column effluent was measured using 
a fluorescence detector (Hitachi High-Technologies 
Corporation, Tokyo, Japan) using a 230-nm excita-
tion wavelength and a 305-nm emission wavelength. 
The lower limit of quantification (LLOQ) was deter-
mined to be 1.6 ng/mL. The percent coefficient of 
variation (%CV) for 5 samples at the LLOQ on 3 days 
(days 1, 2, 5) ranged from 9.2% to 9.6% for R meto-
prolol and from 8.2% to 11.7% for S metoprolol. 
The %CV for 5 replicate samples each of the 4.7-ng/
mL, 15.6-ng/mL, and 46.8-ng/mL standards ranged 
from 0.4% to 8.7% for S metoprolol and from 0.5% 
to 10.5% for R metoprolol on 3 separate days (days 
1, 2, 5). The %CV during system suitability tests 




PK variables for each of the enantiomers were 
 calculated by noncompartmental methods using 
WinNonlin Version 5.2.1 (Pharsight Corp, Mountain 
View, California). PK variables evaluated included 
Cmax, time to reach Cmax (tmax), apparent oral clearance 
(CL/F), terminal elimination rate (λz), and the AUC 
from time 0 to the 24-hour blood draw (AUC0-24 h) 
calculated by the linear trapezoidal rule. 
Concentrations below the LLOQ were removed. 
Area under the curve was extrapolated to 24 hours 
when the 24-hour time point was below the LLOQ 
by extrapolating concentration at 24 hours (last 
concentration above LLOQ·exp(–λz·Δt)) and apply-
ing the linear trapezoidal rule.
Statistical Analysis
PK variables are reported as geometric mean ± stand-
ard deviation. Demographic variables are reported as 
arithmetic mean ± standard deviation. Differences in 
PK and pharmacodynamic variables between study 
phases were evaluated by 2-way analysis of variance 
(ANOVA) with post hoc analysis when appropriate 
by Tukey studentized range test using R Version 
2.8.1 (Vienna, Austria). A sample size of 10 partici-
pants was calculated to detect a 20% increase in 
AUC with coadministration of paroxetine with both 
metoprolol formulations. A paired t test was used to 
compare percent change in AUC with addition of 
paroxetine between metoprolol formulations. A sig-
nificance level of .05 was used for all statistical 
hypothesis testing.
results
Ten healthy male volunteers, aged 28 ± 10 years 
(range, 18-45 years), weight 81.6 ± 9.9 kg (range, 
63.2-94.2 kg), and height 179.0 ± 6.0 cm (range, 
171.5-187.1 cm), gave their written informed con-
sent and participated in the study. Eight participants 
were white and 2 were African American. All par-
ticipants completed the study and were included in 
the final PK analysis. Figures 1 and 2 show average 
plasma concentration versus time curves during 
each of the 4 study phases.
Mean PK variables are summarized in Table I. 
Individual percent changes in AUC0-24 h and S/R AUC 
ratios by subject are listed in Table II. Area under the 
curve of both metoprolol enantiomers for both for-
mulations increased significantly with  paroxetine 
392  •  J Clin Pharmacol 2011;51:389-396
STOUT ET AL
coadministration (Figures 3 and 4). Mean plasma 
AUC of S and R metoprolol enantiomers increased 
during paroxetine coadministration by approxi-
mately 4- and 5-fold, respectively, for metoprolol IR 
and by approximately 3- and 4-fold, respectively, for 
metoprolol ER. The percent increase in AUC with 
coadministration of paroxetine was similar between 
metoprolol IR and ER (P = .35 for S enantiomer, P = 
.56 for R enantiomer). AUC0-24 h was extrapolated in 
all participants in the IR group without paroxetine 
phase (S: 14% total AUC; R: 21%), 4 participants in 
IR with paroxetine phases (S: 2 participants, 2% 
total AUC; R: 2 participants, 4%), 4 participants in 
ER without paroxetine phases (S: 2 participants, 4% 
total AUC; R: 3 participants, 6%), and no partici-
pants in ER with paroxetine phases.
The S/R AUC ratio for metoprolol IR and ER 
decreased with paroxetine coadministration from 
1.64 and 1.65, respectively, to 1.17 and 1.15. All 
participants’ S/R AUC ratios from both metoprolol 
formulations decreased with paroxetine coadminis-
tration, and changes for both formulations were sta-
tistically significant (Figures 5 and 6).
There was no change in heart rate or P-R 
interval on electrocardiogram between baseline and 



























Figure 1. Average plasma concentration versus time curves for 
total metoprolol (S + R) following 50 mg metoprolol immediate 
release (IR). Error bars depict standard deviation. : metoprolol 



























Figure 2. Average plasma concentration versus time curves for 
total metoprolol (S + R) following 100 mg metoprolol extended 
release (ER). Error bars depict standard deviation. : metoprolol 
alone, n = 9; : metoprolol + paroxetine, n = 10.
table I Stereospecific Pharmacokinetic Variables in Healthy Participants (N = 10) for Oral Metoprolol IR 
and ER Given With and Without Paroxetine
Metoprolol Ir 50 mg Metoprolol er 100 mg
Variable Metoprolol enantiomer Without Paroxetine With Paroxetine
Without 
Paroxetine With Paroxetine
AUC0-24 h, ng·h/mL S 138 ± 98 511 ± 116 ** 173 ± 96 599 ± 174 **
R 84 ± 75 436 ± 141 ** 120 ± 71a 521 ± 183 **
CL/F, L/h S 194 ± 171 47 ± 15 * 138 ± 90b 56 ± 46c
R 392 ± 913 56 ± 27 * 292 ± 291d 66 ± 36c
λz, h
−1 S 0.23 ± 0.05 0.13 ± 0.02 ** 0.04 ± 0.03b 0.04 ± 0.03c
R 0.29 ± 0.19 0.14 ± 0.03 * 0.05 ± 0.03d 0.05 ± 0.02c
tmax, h S 1.0 ± 0.4 1.0 ± 0.6 8 ± 3 10 ± 3
R 1.0 ± 0.3 1.1 ± 0.6 5 ± 4a 9 ± 3 *
Cmax, ng/mL S 30 ± 23 81 ± 17 ** 10 ± 5 35 ± 9 *
R 20 ± 20 73 ± 18 ** 8 ± 4a 30 ± 9 *
S/R AUC ratio S/R 1.64 ± 0.25 1.17 ± 0.17 ** 1.65 ± 0.37a 1.15 ± 0.11 **
Values are reported as geometric mean ± standard deviation. IR, immediate release; ER, extended release.
a. n = 9 evaluable.
b. n = 6 evaluable.
c. n = 5 evaluable.
d. n = 7 evaluable.
*P < .05. **P < .001.
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metoprolol-only phases to all metoprolol-paroxetine 
phases, systolic BP decreased from baseline to tmax 
from an average 123 mm Hg at baseline to 113 mm 
Hg at R enantiomer tmax (P < .001) and 114 mm Hg at 
S enantiomer tmax (P < .001, normal <120 mm Hg). 
Diastolic blood pressure did not change significantly 
from baseline to tmax, averaging 66 mm Hg at base-
line, 65 mm Hg at R enantiomer tmax, and 66 mm Hg 
at S enantiomer tmax (normal <80 mm Hg). There 
were no significant differences between metoprolol 
formulations with respect to blood pressure change 
with addition of paroxetine.
Compliance with study medication was complete 
per patient dose diaries. Two possible adverse drug 
events were noted during the study period, with 1 
participant reporting a panic attack on day 4 of par-
oxetine treatment and 1 participant reporting tran-
sient nausea following the second morning dose of 
paroxetine. Neither of these events prevented com-
pletion of the study per protocol.
dIsCussIon
Paroxetine coadministration with metoprolol IR or 
ER significantly increased systemic exposure to S and 
R metoprolol. There is a loss of stereospecific metabo-
lism and a greater increase in R metoprolol exposure 
compared to S metoprolol. There was a similar 
increase in AUC between metoprolol formulations.
We hypothesized that the drug interaction with 
paroxetine would be greater with IR metoprolol than 
ER because the increased drug input rate has greater 
potential to saturate CYP2D6 on hepatic first pass, 
but the results of this investigation indicated a simi-
lar magnitude of effect. CYP2D6 saturation may not 
play a large enough role in metoprolol PK at the 
input rates investigated to demonstrate such an 
effect. In future studies, an input rate-dependent 
stereoselective drug interaction with metoprolol 
may be more easily demonstrated with higher doses. 
One previous PK study of metoprolol IR 100 mg 
table II Percent Change From Baseline in AUC0-24 h and S/R AUC Ratio With Paroxetine Addition to 
Metoprolol IR and Metoprolol ER in Healthy Participants (N = 10)




auC0-24 h (% Change 
With Paroxetine)
s/r auC ratio (% 
Change With 
Paroxetine)
auC0-24 h (% Change 
With Paroxetine)
s/r auC ratio (% 
Change With 
Paroxetine)
1 S 147 −37 199 −32
R 294 338
2 S 303 −44 204 −41
R 615 418
3 S  63 −11  58 −14
R  84  84
4 S 524 −28 666 NAa
R 770 NAa
5 S 446 −15 397 −48
R 546 865
6 S 573 −32 501 −36
R 883 844
7 S 641 −27 350 −42
R 909 674
8 S  64 −17 117 −17
R  98 161
9 S 188 −35 157 −18
R 343 213
10 S 266 −34 207 −27
R 453 320
Mean S 322 −28 286 −31
R 500 435
IR, immediate release; ER, extended release.
a. No detectable R enantiomer plasma concentrations when metoprolol ER was given without paroxetine.
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showed a similar S/R AUC ratio in the absence of 
paroxetine (1.72) and a similar increase in S and R 
AUC with paroxetine coadministration to what was 
observed in the present study (5- and 8-fold, respec-
tively), whereas a previous study of metoprolol IR 
200 mg yielded an S/R AUC ratio of 1.37 in the 
absence of CYP2D6 inhibitor.7,8 This may indicate 
greater CYP2D6 saturation at the 200-mg IR dose, 
which would theoretically be greater influenced by 
the presence of a CYP2D6 inhibitor.
Increased metoprolol exposure with paroxetine 
coadministration could lead to increased beta- 
adrenergic antagonism. Furthermore, a greater pro-
portional increase in exposure to the less beta-1 
selective R enantiomer could result in a loss of cardi-
oselectivity. Some pharmacodynamic effects consist-
ent with increased cardiac beta-adrenergic antagonism 
with metoprolol and paroxetine coadministration 
have been demonstrated. Our study of healthy nor-
mal participants receiving single-dose metoprolol 
showed a significant reduction in resting systolic 
blood pressure with coadministration. A previous 
study of healthy normal participants receiving single-
dose metoprolol showed reductions in exercise-
induced heart rate and systolic blood pressure with 
coadministration.8 A third study in post-MI patients 
receiving multiple-dose coadministration showed 
decreased resting heart rates.9 The present study had 
very limited power to detect pharmacodynamic 
effects of increased metoprolol exposure because it 
examined these effects in a small number of resting 
participants receiving low metoprolol doses. The 
pharmacodynamic impact of increased metoprolol 
exposure is expected to be greatest during periods of 
catecholamine surges (eg, exercise).
Adverse events consistent with excessive beta-
adrenergic antagonism have been reported when 
paroxetine and metoprolol are coadministered and 
include postural hypotension, bradycardia, and 
complete atrioventricular block.9,13 Increases in beta-
adrenergic antagonism are most likely the pharma-
codynamic consequence of increased metoprolol 
exposure, although direct or indirect antiadrenergic 
activity of paroxetine may play a minor role. 
Although most participants in studies to date have 
had no adverse events associated with metoprolol-
paroxetine coadministration, avoidance of this drug 
interaction or preemptive metoprolol dose reduction 





























Figure 3. Metoprolol immediate-release (IR) AUC following 50 mg 
oral dose, with and without paroxetine. —: mean metoprolol AUC 




























Figure 4. Metoprolol extended-release (ER) AUC following 100 mg 
oral dose, with and without paroxetine. —: mean metoprolol AUC 























Figure 6. Metoprolol extended-release (ER) S/R enantiomer AUC 
ratio following 100 mg oral dose, with and without paroxetine. —: 























Figure 5. Metoprolol immediate-release (IR) S/R enantiomer AUC 
ratio following 50 mg oral dose, with and without paroxetine. —: 
mean S/R ratio 1.6 without paroxetine, 1.2 with paroxetine.
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Two potential limitations of this study are the lack 
of CYP2D6 genotype data for participants and the 
low number of blood draws in the terminal portion 
of the dosing interval. First, regarding CYP2D6 geno-
typing, calculated terminal half-lives for R and S 
enantiomers of metoprolol in the absence of paroxet-
ine ranged from 0.9 to 3.7 hours for the R enantiomer 
and 2.1 to 4.1 hours for the S enantiomer; these val-
ues are consistent with tabulated terminal half-lives 
for metoprolol in EMs (R enantiomer 2.8 ± 1 h, S 
enantiomer 2.9 ± 1 h), and all values are greater than 
2 standard deviations lower than tabulated half-lives 
for PMs (R enantiomer 7.7 ± 1.7 h, S enantiomer 7.2 
± 1.5 h).7 Also consistent with an EM phenotype is 
that all participants had baseline S/R AUC ratios 
greater than 1.0 and even maintained values greater 
than 1.0 with paroxetine coadministration, whereas 
tabulated S/R AUC ratios for PMs receiving metopro-
lol alone are typically 1.0 or less.7 Addition of parox-
etine enhanced AUC of both enantiomers and 
decreased S/R ratios in all participants. It is therefore 
unlikely that any participants in this study would be 
correctly classified as PMs via genotyping. With 
respect to blood sampling late in the dosing interval, 
although there was 21% AUC extrapolation in one 
phase of the study suggesting insufficient sampling, 
the data collected were sufficient to characterize the 
drug interaction with paroxetine with both IR and 
ER formulations. A longer period of observation may 
have yielded more λz and CL/F data from partici-
pants in the ER phases of the study but was not nec-
essary to detect the drug interaction.
Dosing and coadministration effects may account 
for some between-formulation differences observed 
in this study. First, paroxetine administration in an 
immediate-release formulation may have resulted in 
variable hepatic drug exposure and CYP2D6 inhibi-
tion across the dosing interval, which could affect 
concentration-time profiles of metoprolol ER and IR 
differently. Second, plasma paroxetine levels were 
not measured, so any variability in exposure to par-
oxetine across the dosing interval cannot be assessed, 
nor can any potential impact of metoprolol or meto-
prolol formulation on paroxetine pharmacokinetics. 
Third, the administration of paroxetine and meto-
prolol simultaneously may have resulted in an 
altered gastric emptying or absorption rates that 
could themselves affect drug input and pharmacoki-
netics of either drug. Twice-daily administration of 
paroxetine and dosing for 7 days prior to metoprolol 
studies were measures taken to minimize paroxetine 
exposure fluctuations and to maintain a dosing 
 strategy typical of clinical practice but would not 
compensate for all of these possible effects.
In conclusion, this study demonstrated a PK drug-
drug interaction between the CYP2D6 inhibitor par-
oxetine and the CYP2D6 substrate metoprolol in both 
IR and ER formulations. The overall magnitude of 
drug interaction was approximately the same with the 
2 formulations. Without an appropriate prospectively 
designed study, input rate-dependent stereoselective 
drug interaction with metoprolol requires further test-
ing. However, this concept should be of great interest 
because input rate-dependent interactions may have 
potentially important clinical ramifications.
Financial disclosure: The study was funded by a grant from 
AstraZeneca, as well as the University of Michigan General Clini-
cal Research Unit (NIH grant #M01-RR000042) and the Michigan 
Clinical Research Unit (NIH grant #UL1RR024986). The project 
described was supported by grant number UL1RR024986 from the 
National Center for Research Resources. The content is solely the 
responsibility of the authors and does not necessarily represent 
the official views of NCRR or the National Institutes of Health. BB, 
LW: consultant and speaker’s bureau, AstraZeneca.
reFerenCes
1. Boucher M, Duchêne-Marullaz P, Moundanga JL. Studies on the 
stereoisomers of beta-adrenoceptor antagonists in conscious A-V 
blocked dogs. Br J Pharmacol. 1986;89:119-127.
2. Wahlund G, Nerme V, Abramsson T, Sjöquist PO. The beta 1- 
and beta 2-adrenoceptor affinity and beta 1-blocking potency of 
S- and R-metoprolol. Br J Pharmacol. 1990;99:592-596.
3. Borg KO, Carlsson E, Hoffmann KJ, Jönsson TE, Thorin H, 
Wallin B. Metabolism of metoprolol-(3-h) in man, the dog, and the 
rat. Acta Pharmacol Toxicol (Copenh). 1975;35(suppl 5):125-135.
4. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use 
of quinidine inhibition to define the role of the sparteine/debriso-
quine cytochrome P450 in metoprolol oxidation by human liver 
microsomes. J Pharmacol Exp Ther. 1988;247:242-247.
5. Dayer P, Leemann T, Marmy A, Rosenthaler J. Interindividual 
variation of beta-adrenoceptor blocking drugs, plasma concentra-
tion and effect: influence of genetic status on behaviour of atenolol, 
bopindolol and metoprolol. Eur J Clin Pharmacol. 1985;28:149-153.
6. Jonkers RE, Koopmans RP, Portier EJ, van Boxtel CJ. Debrisoquine 
phenotype and the pharmacokinetics and beta-2 receptor pharma-
codynamics of metoprolol and its enantiomers. J Pharmacol Exp 
Ther. 1991;256:959-966.
7. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, 
Woods HF. Differential stereoselective metabolism of metoprolol 
in extensive and poor debrisoquine metabolizers. Clin Pharmacol 
Ther. 1983;34:732-737.
8. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine 
affects metoprolol pharmacokinetics and pharmacodynamics in 
healthy volunteers. Clin Pharmacol Ther. 2000;67:283-291.
9. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, 
Bertilsson L. Inhibition of metoprolol metabolism and potentiation 
396  •  J Clin Pharmacol 2011;51:389-396
STOUT ET AL
of its effects by paroxetine in routinely treated patients with acute 
myocardial infarction (AMI). Eur J Clin Pharmacol. 2008;64:275-282.
10. Bleske BE, Welage LS, Rose S, Amidon GL, Shea MJ. The effect of 
dosage release formulations on the pharmacokinetics of propranolol 
stereoisomers in humans. J Clin Pharmacol. 1995;35:374-378.
11. Bleske BE, Welage LS, Touchette MA, Edwards DJ, Rodman 
DP, Shea MJ. Evaluation of dosage-release formulations on inhibition 
of drug clearance: effect of sustained- and immediate-release 
verapamil on propranolol pharmaocokinetic parameters. Ther 
Drug Monit. 1994;16:216-220.
12. Karim A, Piergies A. Verapimil stereoisomerism: enantiomeric 
ratios in plasma dependent on peak concentrations, oral input 
rate, or both. Clin Pharmacol Ther. 1995;58:174-184.
13. Onalan O, Cumurcu B, Bekar L. Complete atrioventricular 
block associated with concomitant use of metoprolol and parox-
etine. Mayo Clin Proc. 2008;83:595-599.
For reprints and permission queries, please visit SAGE’s Web site at http://www.sagepub.com/journalsPermissions.nav.
